Total Live Articles: 430

Scabies

NICE CKS Scabies. Last revised: Sep 2025.

Scabies

Scabies is a highly contagious skin infestation caused by the mite Sarcoptes scabiei, characterised by intense pruritus and a papular rash due to hypersensitivity reactions to the mite and its products.

This updated UKMLA guide to scabies is based on PCDS guidance, which covers causes, transmission, risk factors, symptoms, diagnosis, and management.

Causes and Pathophysiology

Scabies is caused by infestation with the mite: Sarcoptes scabiei (a human parasite)

The female mite burrows into the stratum corneum of the skin and lays eggs → delayed type IV hypersensitivity reaction to the mites, eggs, and faeces.

Transmission and Risk Factors

Scabies is typically transmitted via close / prolonged skin contact with an infected person:

  • Often transmitted via sexual contact
  • Transmission via shared clothing or bedding can occur
  • Transmission via casual contact (e.g. handshake) is unlikely

Risk factors:

  • Close contact with an infested person
  • Tropical and developing countries
  • High levels of poverty and social deprivation
  • Crowded living conditions and institutionalisation (e.g. nursing homes, long-term care facilities, prisons, military barracks)
  • Winter months

Clinical Features

Symptoms Primary feature: generalised itching

  • The itching is often severe and is worse at night
  • Symptoms begin 3–6 weeks after primary infestation, but occur earlier (at 1–3 days) in a reinfested person

The absence of itching does NOT exclude scabies (e.g. young babies and in people with neurological conditions with decreased / loss of sensation)

Signs

Scabies is infectious before the rash develops

Location and distribution:

  • Fingers (including interdigital spaces)
  • Wrists
  • Extensor surface of limbs
  • Periumbilical area, waist, buttocks
  • Breast, axillary folds, genitalia

Appearance:

  • Erythematous, small papules
  • Excoriation marks from scratching
  • Haemorrhagic crusts
  • Pathognomic sign: linear burrow (thin, brown-grey lines produced by moving mites)

Nodular lesions may also be seen, especially on the penis and scrotum in men, buttocks, groin, and the axillary regions

Relevant history
  • Whether itching is reported by family members or close contacts
  • Patient’s living conditions (?overcrowded living conditions)
  • Any new or multiple sexual contact

Crusted scabies (Norwegian scabies)

  • Caused by hyperinfestation with thousands or millions of mites
  • It develops mainly in immunocompromised patients (e.g. HIV)
  • Pruritus is mild or absent due to impaired immune response
  • Skin lesions consist of generalised, poorly defined, erythematous, fissured plaques covered by scales and crusts

Complications

  • Secondary bacterial infection (e.g. impetigo, folliculitis)
  • Nodular scabies (pruritic nodules of the axillae, groin, and male genitalia can persist for weeks or months after treatment)
  • Secondary eczematisation (due to scratching and/or irritant effects of topical medications)

Investigation and Diagnosis

Scabies is primarily a clinical diagnosis.

The following tests can provide a definitive diagnosis (if equipment and expertise allow, and used mainly if there is diagnostic uncertainty, atypical presentation, failed treatment etc.):

  • Ink burrow test: +ve test would show dark zigzagged line running across and away from the lesion (due to ink tracking down the mite burrow)
  • Skin scrapings microscopy – presence of mites / eggs / mite faecal material confirms the diagnosis

Management

Referral Criteria

Seek specialist advice if:

  • Scabies in <2 m/o (scabies is rare in this age group and permethrin cream is only licensed for ≥2 months)
  • Crusted scabies (hospital admission may be required)
    • Isolation is necessary
    • Treatment would likely involve topical insecticide + oral ivermectin
    • It may be necessary to investigate for underlying immunodeficiency

General / Conservative Management

Advise that bedding, clothing, and towels (and those of all potentially infested contacts) should be decontaminated by washing at a high temperature (at least 60°C) and drying in a hot dryer, or dry-cleaning, or by sealing in a plastic bag for at least 72 hours

Anti-Scabies (Pharmacological) Treatment

There are 2 treatment regimens with similar effectiveness for classic scabies (i.e. non-crusted scabies):

  • Permethrin 5% cream, OR
  • Oral ivermectin

For both, give 1 dose / application initially, then repeat 1 more dose after 7 days

Both have similar effectiveness; choose the regimen based on the following factors:

Consider avoiding permethrin cream if Consider avoiding oral ivermectin if
  • Patients with pre-existing eczema or other skin conditions which may lead to hypersensitivity
  • Broken or secondarily infected skin
  • Pregnant and breastfeeding (manufacturer advises to avoid)
  • Severe hepatic impairment (contraindicated)
  • <15 kg weight

Advise that itching may continue for up to 4 weeks after successful treatment of scabies.

  • Re-treatment should be advised if itching persists for>2-4 weeks after the last treatment application and/or new burrows have appeared
  • Resistant cases can be treated with topical permethrin PLUS oral ivermectin OR refer for specialist advise.

Contact Management

All the following should be treated with anti-scabies treatment, even if asymptomatic:

  • Household members
  • Sexual partners within the past month
  • Any other close personal contacts

Post-Scabetic Itch

Post-scabetic itch refers to persistent itching that continues after successful treatment of scabies, despite eradication of the mites. Management:

  • Crotamiton 10% cream
  • If scabies mites have definitely been eradicated: topical hydrocortisone 1%

Also consider nighttime sedating antihistamine (e.g. chlorphenamine) to improve sleep and reduce scratching

References

Related Articles

Impetigo

Folliculitis, Furuncles, and Carbuncles

Atopic Dermatitis (Eczema)

Contact Dermatitis

Human Immunodeficiency Virus (HIV)

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.